Clinical Trial Update: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients [Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 2 study evaluating TTX-030 in combination with chemotherapy, with or without budigalimab, for first-line metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• TTX-030
• budigalimab (budigalimab)

Snippet

Sponsor: Trishula Therapeutics, Inc. | Conditions: Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING